ArticleClinical and translational gastroenterology2016
A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity.
Article in Clinical and translational gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Rational Fabrication of Copper Nanoclusters and In Vitro Study of Antioxidant Property.Nanomaterials (Basel, Switzerland) · 2025Article
- Interface between Resolvins and Efferocytosis in Health and Disease.Cell biochemistry and biophysics · 2024Review
- P2rx1 deficiency alleviates acetaminophen-induced acute liver failure by regulating the STING signaling pathway.Cell biology and toxicology · 2023Article
- CXCL5 Promotes Acetaminophen-Induced Hepatotoxicity by Activating Kupffer Cells.International journal of molecular sciences · 2023Article
- The molecular mechanisms of acetaminophen-induced hepatotoxicity and its potential therapeutic targets.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Sapidolide A alleviates acetaminophen-induced acute liver injury by inhibiting NLRP3 inflammasome activation in macrophages.Acta pharmacologica Sinica · 2022Article
- Molecular pathogenesis of acetaminophen-induced liver injury and its treatment options.Journal of Zhejiang University. Science. B · 2022Review
- The complex roles of neutrophils in APAP-induced liver injury.Cell proliferation · 2021Review
- Commonly Prescribed and Over-the-Counter Drugs as Secondary Causes of Osteoporosis-Part One.Integrative medicine (Encinitas, Calif.) · 2021Article
- Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease.Pathogens (Basel, Switzerland) · 2021Review
- The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury.Frontiers in pharmacology · 2021Review
- Limited potential of resolvin D1 in treatment of cholestatic liver fibrosis.Hepatobiliary surgery and nutrition · 2020Article
- Mechanisms and pathophysiological significance of sterile inflammation during acetaminophen hepatotoxicity.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2020Review
- Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions.Redox biology · 2018Review
- Effects of rosmarinic acid on acetaminophen-induced hepatotoxicity in male Wistar rats.Pharmaceutical biology · 2017Article
- Interleukin-1 inhibition facilitates recovery from liver injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice.Liver international : official journal of the International Association for the Study of the Liver · 2017Article
- Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure.Journal of hepatology · 2017Review
- Low-dose acetaminophen induces early disruption of cell-cell tight junctions in human hepatic cells and mouse liver.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesAcetaminophen (APAP)-induced hepatotoxicity is a major cause of morbidity and mortality. The current pharmacologic treatment for APAP hepatotoxicity, N-acetyl cysteine (NAC), targets the initial metabolite-driven injury but does not directly affect the host inflammatory response. Because of this, NAC is less effective if given at later stages in the disease course. Resolvins, a novel group of lipid mediators shown to attenuate host inflammation, may be a therapeutic intervention for APAP hepatotoxicity.
methodsThe temporal patterns of liver injury and neutrophil activation were investigated in a murine model of APAP hepatotoxicity. In addition, the effect of neutrophil depletion and resolvin administration on the severity of liver injury induced by APAP was studied. In vitro studies to investigate the mechanism of resolvin effect on hepatocyte injury and neutrophil adhesion were performed.
resultsWe demonstrate that hepatic neutrophil activation occurs secondary to the initial liver injury induced directly by APAP. We also show that neutrophil depletion attenuates APAP-induced liver injury, and administration of resolvins hours after APAP challenge not only attenuates liver injury, but also extends the therapeutic window eightfold compared to NAC. Mechanistic in vitro analysis highlights resolvins' ability to inhibit neutrophil attachment to endothelial cells in the presence of the reactive metabolite of APAP.
conclusionsThis study highlights the ability of resolvins to protect against APAP-induced liver injury and extend the therapeutic window compared to NAC. Although the mechanism for resolvin-mediated hepatoprotection is likely multifactorial, inhibition of neutrophil infiltration and activation appears to play an important role.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.